Brief Communication
Sample collection
EDTA whole blood (5 ml) was collected in a vacutainer (Bekton and Dickinson, USA), and urine (10 ml) and saliva samples were collected in a sterile wide-mouth container (Hi-media laboratories). Saliva was collected after ensuring no food, mint or medicines had been taken 30 min before sample collection and were transported to clinical virology laboratory in cold container.
Whole blood (5 ml) was aliquoted into storage vials. Urine specimens were centrifuged at 3500 rpm for 30 min and suspended with viral transport medium (VTM). Saliva was suspended with VTM. All samples were stored at −80°C.
Quantitation of cytomegalovirus DNA by real-time PCR
Q real-time PCR was performed with a commercial CMV assay (Cat No. 69-003B, R-gene™, France) using an ABI 7900 Fast Real-Time PCR instrument (SDS Version: 2.4). Positive control and negative control were included in all assays. The lower limit of detection of the assay was estimated to be <50 copies/ml (as per the manufacturer's instruction). DNA integrity of the samples was confirmed by the presence of internal control DNA. The test sample result was reported as numeric concentration in copies per millilitre of whole blood or urine or saliva.
reSultS
CMV viral load (VL) ranges from 135 to 10,440,387 copies/ml in whole blood; 53 to 3,235,149 copies/ml in urine and 384 to 107,694 copies/ml in saliva. The detection rate of CMV was found to be 27% (n = 8) in different samples including whole blood, urine and saliva. The recovery of CMV DNA in whole blood or urine or saliva samples was 73% (n = 22) of the study population. Among 30 PRTRs, 53% (n = 16) of the PRTRs did not shed virus in the saliva [ Table 2 ].
Viral load with ≥1000 copies/ml
Among n = 30 PRTRs, CMV VL with ≥1000 copies/ml was detected in 56.7% (n = 17) of which 64.7%% (n = 11/17) belonged to Group B2, 23.5% (n = 4/17) belonged to Group B3 and 11.8% (n = 2) belonged to Group BI.
Viral load with ≤1000 copies/ml
CMV VL with ≥50 to ≤1000 copies/ml was found in 16.7% (n = 5) of the PRTRs, of which 40% (n = 2) belonged to Group A and 20% (n = 1) belonged to each Group B1, B2 and B3.
Cytomegalovirus viral load in salivary samples
CMV VL in saliva was seen in 7% of PRTR, with an absence of VL in whole blood, urine and evidence of deranged renal parameters. CMV VL with >1000 copies/ml in the saliva was observed 30% (n = 9) of the study participants, in which one participant had detectable VL only in saliva but did not detected in blood and urine. Among PRTRs with severe gastrointestinal manifestations with normal renal parameter (n = 3) and with increased renal parameters (n = 3), a high viral load in saliva was observed. However the viral load was less to undetectable in blood and urine samples.
CMV VL with <1000 copies/ml in the saliva was observed five PRTRs in which one participant belongs to Group B2 had detectable CMV only in saliva. CMV DNA did not observed in saliva samples among any of the asymptomatic PRTRs. Antiviral therapy was initiated with significant clinical improvement. The details of two PRTRs in whom only saliva sample tested positive for CMV are given below.
Case 1
A 64-year-old PRTR (11 years' post-transplant) reported with the complaints of bloody diarrhoea and vomiting. His cell counts, blood sugar, electrolytes, liver functions and urine routine were normal. CMV pp65 anti-genemia was positive. CMV DNA was not detected in either whole blood or urine. CMV was found to be 7824 copies/ml in the saliva. The patient was treated with intravenous ganciclovir followed by oral valacyclovir; he recovered completely after completion of the course of antiviral therapy.
Case 2
A 43-year-old female (17 years' post-transplant) had complaints of debilitating chronic diarrhoea with normal cell counts and normal profile of blood sugars, electrolytes and liver function. CMV DNA was found to be 974 copies/ml in the saliva but not detected in the whole blood and urine. She recovered from the chronic diarrhoea following intravenous ganciclovir therapy.
In both cases, other herpes viruses (HSV-1, HSV-2 and varicella zoster virus [VZV]) were ruled out by Q real-time PCR. Bacterial and parasitic causes of diarrhoea were also ruled out. Co-occurrence of EBV was found in one PRTR. PRTRs with elevation of renal parameters in serum GI: Gastro intestinal, ALT: Alanine transaminase, CMV: Cytomegalovirus, PRTRs: Post-renal-transplant recipients diScuSSiOn CMV disease is known to cause direct and indirect effects, leading to complications in PRTRs. [5] In this study, we used ppUL83 gene for CMV DNA quantitation as it encodes pp65 protein of CMV and is an early marker of active CMV replication.
All symptomatic PRTRs in our study had more than 1000 copies/ml of CMV DNA (saliva (n = 9), urine (n = 11) and whole blood (n = 8). Detection of CMV DNA has been reported in saliva during early stages of reactivation of CMV even before its appearance in the whole blood. [6] [7] [8] Compartmentalised or localised CMVD may be suspected due to the absence of detectable virus in the blood. [9] About 30% had high CMV VL (≥1000 copies/ml) in the saliva among symptomatic PRTRs. Furthermore, there were five cases where the CMV-positive participants tested positive in blood and negative in saliva.
To our knowledge, this the first study to document CMVD in PRTRs using different samples. Based on our experience, compartmentalised CMVD may be detected earlier in saliva than in other samples and can be used for monitoring high-risk individuals along with sampling of blood and urine.
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